Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HGS Europe

- PMLiVE

Choosing wisely

How to make the best of emerging markets

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

- PMLiVE

Taking a strategic approach

Janssen's Cyril Titeux on responding to the industry's pricing, access and reputational challenges

- PMLiVE

Oncology directions

With increasingly expensive cancer drugs, what price should be paid for innovation?

- PMLiVE

Critical thinking

Assessing the Darwinian model of mutation in pharmaceutical companies

- PMLiVE

Pharma must ‘create new social contract’

New task force established in UK to assess public’s view of the value and risk of medicines

- PMLiVE

Nothing but a shell game

Is health insurance a rigged game?

- PMLiVE

Making savings from European drugs budgets

National programmes of cuts are the order of the day

Friend or foe?

Payer relationship might have unintended consequences

Novartis day

Novartis heart drug may see novel pricing plan

Swiss firm looking to risk share with payers based on clinical outcomes

- PMLiVE

Opdivo approved via UK’s early drug access scheme

Bristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

- PMLiVE

The importance of real-world data to the pharma industry

It is a crucial time to for pharma and other stakeholders to demonstrate medicines' value

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links